Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vascular system, which may lead to right-heart failure or early death in the absence of effective treatment. The current therapy for PAH mainly includes phosphodiesterase inhibitors, prostanoids and endothelin receptor antagonists. These, however, have adverse effects when administered via conventional routes. There is a clear and critical need for the development of a novel delivery system that can efficiently deliver the drug to lung vasculature and minimize adverse effects. This article summarizes the inhalation devices and recent patents in the area of inhalable therapy for the treatment of PAH. Various patents are discussed that describe the application of inhalable therapy to target lung vasculature and to reduce dose-related side effects in PAH treatment. Entry of some inhalable delivery approaches into clinical trials is the result of progress in inhalable therapies for the treatment of PAH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
